1997
Health after coronary stenting or balloon angioplasty: Results from the Stent Restenosis Study
Krumholz H, Cohen D, Williams C, Baim D, Brinker J, Cabin H, Heuser R, Hirshfeld J, Leon M, Moses J, Savage M, Cleman M. Health after coronary stenting or balloon angioplasty: Results from the Stent Restenosis Study. American Heart Journal 1997, 134: 337-344. PMID: 9327686, DOI: 10.1016/s0002-8703(97)70065-6.Peer-Reviewed Original ResearchConceptsStent Restenosis StudyCoronary stentingBalloon angioplastyRestenosis StudyDuke Activity Status IndexPalmaz-Schatz coronary stentingCanadian Cardiovascular Society classificationPalmaz-Schatz coronary stent implantationPercutaneous transluminal coronary angioplastyU.S. clinical sitesLong-term HRQoLForm Health SurveyHealth-related qualityMedical Outcomes StudyTransluminal coronary angioplastyCoronary stent implantationConventional balloon angioplastyDisease-specific measuresAngiographic restenosisConventional angioplastyIschemic eventsBodily painConsecutive patientsCoronary angioplastyCardiovascular perspective
1996
Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators.
Mark D, Talley J, Topol E, Bowman L, Lam L, Anderson K, Jollis J, Cleman M, Lee K, Aversano T, Untereker W, Davidson-Ray L, Califf R. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. Circulation 1996, 94: 629-35. PMID: 8772681, DOI: 10.1161/01.cir.94.4.629.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplastyAntibodies, MonoclonalAnticoagulantsAspirinBlood TransfusionCosts and Cost AnalysisDouble-Blind MethodFemaleHeparinHumansImmunoglobulin Fab FragmentsInfusions, IntravenousInjections, IntravenousMaleMiddle AgedMyocardial IschemiaPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexRecurrenceStentsTreatment OutcomeUnited StatesConceptsHigh-risk coronary angioplastyC7E3 FabIschemic eventsCoronary angioplastyInitial hospitalizationPlatelet glycoprotein IIb/IIIa inhibitionGlycoprotein IIb/IIIa inhibitionIIb/IIIa inhibitionAggressive platelet inhibitionBaseline medical costsIschemic end pointsReduced ischemic eventsAcute ischemic eventsCost of therapyEPIC trialMajor bleedingBleeding episodesIschemic complicationsStandard carePlatelet inhibitionHospitalization ratesReceptor antibodiesHospital costsMedical costsMedicare fee